EN DE
Watch Staidson Beijing Biopharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Staidson Beijing Biopharma (300204) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Staidson Beijing Biopharma stock ¥10.76, price ¥17.94, that is 40.0% below the price, quality 45 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100001237

SB Staidson Beijing Biopharma logo Thin data Nov 10, 2026

Staidson Beijing Biopharma

300204 · SHE
Very expensive, weak quality

Our calculation puts a fair price 40% below what the stock costs today.

Low debt
Quality 45/100
Mixed Growth (revenue 5y −12.3 %/yr in CNY)
Revenue last quarter 26% below a year ago.
Fair value ¥10.76 · Strongly overvalued
Loss-making · -47.9% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Staidson Beijing Biopharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥61.00 ¥5.45 Fair Value ¥10.76 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ¥5.45 – ¥61.00 · fair‑value band ¥8.07 – ¥13.45 · the ¥17.94 price screens above the ¥10.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Staidson Beijing Biopharma in your weekly email

Every Wednesday you see whether Staidson Beijing Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China.

Show moreShow less

The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases.

Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Stock analysis

Staidson Beijing Biopharma (300204) currently trades at ¥17.94, while our estimate is ¥10.76, 40% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥8.07 (bear) to ¥13.45 (bull), the price of ¥17.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2016: revenue and profit before it include the divested business. Growth is measured afresh from 2016.

Staidson Beijing Biopharma reported revenue of 220M CNY in FY2025 versus 584M CNY in FY2021, a compound −21.6%/yr. Reported net income was −77.8M CNY in FY2025.

Key figures

Market cap 9.8B CNY (≈ $1.5B) Small · P/S ratio 49.5 · EPS (TTM) ¥−0.1900 · Dividend yield 0.0% · Net margin −47.9% · Return on equity −10.6% · Return on assets (EBIT) −12.6% (5-year average) · Operating margin −58.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −40%, 300204 screens richer than that median.

Fair Value

Bear ¥8.07 Fair Value ¥10.76 Bull ¥13.45
Price ¥17.94 · Downside -40.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 88
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2016: revenue and profit before it include the divested business. Growth is measured afresh from 2016.
Revenue growth 1 year
−32.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36.5% (2020) → −35.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300204 screens overvalued: fair value 40% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Staidson Beijing Biopharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −40.0% · Below median
Profitability
Return on assets −6.1% · Above median
Net margin (12 months) −47.9% · Below median
Operating margin (12 months) −58.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −26.3% · Bottom 25%
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 11.95× · Priciest 25%
P/S (12 months) 52.31× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 300204
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 300204
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 300204
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 300204
argenx SE ARGX $971.55 $908.40 −7% vs 300204
CSL Limited CSL A$201.68 A$181.40 −10% vs 300204
Moderna, Inc MRNA $250.83 $158.70 −37% vs 300204
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 300204
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 300204
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 300204

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Staidson Beijing Biopharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Staidson Beijing Biopharma Fair Value". https://www.fairvalue-calculator.com/stock/300204

Frequently asked questions

Is Staidson Beijing Biopharma (300204) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥10.76 versus a price of ¥17.94, about 40% lower (overvalued).
What is the fair value of 300204?
Our estimate for Staidson Beijing Biopharma is ¥10.76 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥17.94.
What is the quality score of 300204?
Staidson Beijing Biopharma has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Staidson Beijing Biopharma (300204)?
Our calculated price target is the estimate of ¥10.76 (as of Nov 10, 2026). Cautious scenario ¥8.07, optimistic scenario ¥13.45. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Staidson Beijing Biopharma stock forecast for 2026?
Our estimate puts fair value at ¥10.76, about 40% lower versus a price of ¥17.94 (overvalued). Cautious scenario ¥8.07, optimistic scenario ¥13.45. The calculation is refreshed regularly with new filings.
What is the revenue of Staidson Beijing Biopharma (300204)?
Staidson Beijing Biopharma reported trailing-twelve-month revenue of about 188M CNY (latest available figure, as of Nov 10, 2026).
Does Staidson Beijing Biopharma pay a dividend?
Staidson Beijing Biopharma currently shows a dividend yield of 0.01% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Staidson Beijing Biopharma (300204)?
Staidson Beijing Biopharma has a dividend yield of 0.0%.
What is the intrinsic value of Staidson Beijing Biopharma (300204)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Staidson Beijing Biopharma it is ¥10.76 per share (as of Nov 10, 2026), against a price of ¥17.94.
Is Staidson Beijing Biopharma stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 300204 trades above its calculated fair value: price ¥17.94, fair value ¥10.76, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300204?
No. The price is what the market pays today (¥17.94); the fair value is what the company's own numbers justify (¥10.76). For Staidson Beijing Biopharma the two are ¥7.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Staidson Beijing Biopharma worth?
The market values Staidson Beijing Biopharma at about 9.8B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥17.94; our models calculate a fair value of ¥10.76 per share.
What do the bullish and bearish scenarios say about 300204?
Our models span a range for Staidson Beijing Biopharma: cautious scenario ¥8.07, base ¥10.76, optimistic ¥13.45 per share (as of Nov 10, 2026, price ¥17.94). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Staidson Beijing Biopharma (300204)?
Balance-sheet figures for Staidson Beijing Biopharma (as of Nov 10, 2026): return on equity −10.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 300204 from its 52-week high?
Staidson Beijing Biopharma trades at ¥17.94, about 54% below its 52-week high of ¥39.30 and 7% above the low of ¥16.73 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.76 is for.
Which stocks are comparable to Staidson Beijing Biopharma?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Staidson Beijing Biopharma stock attractive at the current price?
The data as of Nov 10, 2026: price ¥17.94, calculated fair value ¥10.76 (−40%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Staidson Beijing Biopharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Staidson Beijing Biopharma (300204)?
The closing price on Nov 10, 2026 was ¥17.94. Our estimate is ¥10.76, about 40% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Staidson Beijing Biopharma right now?
The price sits above even our optimistic bull case (¥13.45). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Staidson Beijing Biopharma

How large is the market capitalisation of Staidson Beijing Biopharma (300204)?
The market capitalisation of Staidson Beijing Biopharma is 9.8B CNY (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Staidson Beijing Biopharma (300204)?
The price-to-sales ratio of Staidson Beijing Biopharma is 49.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Staidson Beijing Biopharma (300204)?
Earnings per share at Staidson Beijing Biopharma are ¥−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Staidson Beijing Biopharma (300204)?
The dividend yield of Staidson Beijing Biopharma is 0.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Staidson Beijing Biopharma (300204)?
The net margin of Staidson Beijing Biopharma is −47.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Staidson Beijing Biopharma (300204)?
The return on equity (ROE) of Staidson Beijing Biopharma is −10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Staidson Beijing Biopharma (300204)?
On an EBIT basis the return on assets of Staidson Beijing Biopharma is −12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Staidson Beijing Biopharma (300204)?
The operating margin of Staidson Beijing Biopharma is −58.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Staidson Beijing Biopharma (300204)?
Revenue at Staidson Beijing Biopharma is growing −26.3% versus a year earlier (3y avg −26.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Staidson Beijing Biopharma (300204)?
Earnings per share at Staidson Beijing Biopharma are growing −80.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Staidson Beijing Biopharma (300204) generate?
The free cash flow of Staidson Beijing Biopharma is −202M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Staidson Beijing Biopharma (300204) hold?
Staidson Beijing Biopharma holds more cash than debt, 23.8M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Staidson Beijing Biopharma in the live analysis

One click puts Staidson Beijing Biopharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.